Assyro AI

Orange Book product · Brand (NDA)

CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER

NICARDIPINE HYDROCHLORIDE

Brand (NDA)NDA 019734RX CHIESI

At a glance

Jul 31, 2008

Approved

Brand (NDA)

Application

Not listed

TE code

6

Listed patents

Key dates

  1. Approval

    FDA approval date of this drug product.

    Jul 31, 2008

    18 yr 2 mo ago

  2. Today

  3. Patent 10758616 expires

    Listed drug product patent expiration.

    Apr 18, 2027

    in 10 mo

  4. Patent 11547758 expires

    Listed method-of-use patent (U-1029) expiration.

    Apr 18, 2027

    in 10 mo

  5. Patent 7659291 expires

    Listed method-of-use patent (U-1029) expiration.

    Apr 18, 2027

    in 10 mo

  6. Patent 8455524 expires

    Listed method-of-use patent (U-1029) expiration.

    Apr 18, 2027

    in 10 mo

  7. Patent 7612102 expires

    Listed drug product patent expiration.

    Dec 26, 2027

    in 1 yr 7 mo

  8. Patent 9364564 expires

    Listed drug product patent expiration.

    Dec 26, 2027

    in 1 yr 7 mo

Pharmaceutical detail

Active ingredient

NICARDIPINE HYDROCHLORIDE

Strength

20MG/200ML (0.1MG/ML)

Dosage form

INJECTABLE

Route

INTRAVENOUS

TE code

Not listed

Application

NDA 019734

Product number

002

Marketing status

RX

Reference listed drug (RLD)

Yes

Reference standard (RS)

Yes

Active-ingredient family

View full family

This is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.

Listed patents (6)

Patents listed in the FDA Orange Book for this product, with expiration date and patent type.
PatentExpiresInType
10758616Apr 18, 2027in 10 mo
Product
11547758Apr 18, 2027in 10 mo
U-1029
7659291Apr 18, 2027in 10 mo
U-1029
8455524Apr 18, 2027in 10 mo
U-1029
7612102Dec 26, 2027in 1 yr 7 mo
Product
9364564Dec 26, 2027in 1 yr 7 mo
Product
Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.